I-Meta-Iodobenzylguanidine Single-Photon Emission Computerized Tomography/Computerized Tomography Scintigraphy in the Management of Neuroblastoma

Overview

Journal Indian J Nucl Med

Specialty Nuclear Medicine

Date 2021 Oct 18

PMID 34658554

Citations 1

Authors

Lorenzo Biassoni

Laura Privitera

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is the most common pediatric extracranial solid tumor. High-risk neuroblastoma is the most frequent presentation with an overall survival of approximately 50%. I-meta-iodobenzylguanidine (I-mIBG) scintigraphy in the assessment of the primary tumor and its metastases at diagnosis and after chemotherapy is a cornerstone imaging modality. In particular, the bulk of skeletal metastatic disease evaluated with I-mIBG at diagnosis and the following chemotherapy has a prognostic value. Currently, single-photon emission computerized tomography/computerised tomography (SPECT/CT) is considered a fundamental part of I-mIBG scintigraphy. I-mIBG SPECT/CT is a highly specific and sensitive imaging biomarker and it has been the basis of all existing neuroblastoma trials requiring molecular imaging. The introduction of SPECT/CT has shown not only the heterogeneity of the mIBG uptake within the primary tumor but also the presence of completely mIBG nonavid metastatic lesions with mIBG-avid primary neuroblastomas. It is currently possible to semi-quantitatively assess tracer uptake with standardized uptake value, which allows a more precise evaluation of the tracer avidity and can help monitor chemotherapy response. The patchy mIBG uptake has consequences from a theranostic perspective and may partly explain the failure of some neuroblastomas to respond to I-mIBG molecular radiotherapy. Various positron emission tomography tracers, targeting different aspects of neuroblastoma cell biology, are being tested as possible alternatives to I-mIBG.

Citing Articles

Predicting event-free survival after induction of remission in high-risk pediatric neuroblastoma: combining I-MIBG SPECT-CT radiomics and clinical factors.

Feng L, Yang X, Wang C, Zhang H, Wang W, Yang J Pediatr Radiol. 2024; 54(5):805-819.

PMID: 38492045 DOI: 10.1007/s00247-024-05901-z.

References

Dubois S, Mody R, Naranjo A, Van Ryn C, Russ D, Oldridge D . MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2017; 64(11). PMC: 5605392. DOI: 10.1002/pbc.26545. View

Park J, Bagatell R, Cohn S, Pearson A, Villablanca J, Berthold F . Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017; 35(22):2580-2587. PMC: 5676955. DOI: 10.1200/JCO.2016.72.0177. View

Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman M, Lopci E . Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018; 45(11):2009-2024. DOI: 10.1007/s00259-018-4070-8. View

Nadel H . SPECT/CT in pediatric patient management. Eur J Nucl Med Mol Imaging. 2014; 41 Suppl 1:S104-14. DOI: 10.1007/s00259-014-2697-7. View

Decarolis B, Schneider C, Hero B, Simon T, Volland R, Roels F . Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study. J Clin Oncol. 2013; 31(7):944-51. DOI: 10.1200/JCO.2012.45.8794. View

Applebaum M, Vaksman Z, Lee S, Hungate E, Henderson T, London W . Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2016; 72:177-185. PMC: 5258837. DOI: 10.1016/j.ejca.2016.11.022. View

Pinto N, Applebaum M, Volchenboum S, Matthay K, London W, Ambros P . Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol. 2015; 33(27):3008-17. PMC: 4567703. DOI: 10.1200/JCO.2014.59.4648. View

Yanik G, Parisi M, Naranjo A, Nadel H, Gelfand M, Park J . Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. J Nucl Med. 2017; 59(3):502-508. PMC: 5868501. DOI: 10.2967/jnumed.117.195883. View

Liu B, Servaes S, Zhuang H . SPECT/CT MIBG Imaging Is Crucial in the Follow-up of the Patients With High-Risk Neuroblastoma. Clin Nucl Med. 2018; 43(4):232-238. DOI: 10.1097/RLU.0000000000001984. View

10.

Sharp S, Trout A, Weiss B, Gelfand M . MIBG in Neuroblastoma Diagnostic Imaging and Therapy. Radiographics. 2016; 36(1):258-78. DOI: 10.1148/rg.2016150099. View

11.

cerny I, Prasek J, Kasparkova H . Superiority of SPECT/CT over planar 123I-mIBG images in neuroblastoma patients with impact on Curie and SIOPEN score values. Nuklearmedizin. 2016; 55(4):151-7. DOI: 10.3413/Nukmed-0743-15-05. View

12.

Yanik G, Parisi M, Shulkin B, Naranjo A, Kreissman S, London W . Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. J Nucl Med. 2013; 54(4):541-8. PMC: 5503147. DOI: 10.2967/jnumed.112.112334. View

13.

Gains J, Aldridge M, Mattoli M, Bomanji J, Biassoni L, Shankar A . 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun. 2020; 41(11):1169-1177. DOI: 10.1097/MNM.0000000000001265. View

14.

Humphries P, Sebire N, Siegel M, Olsen O . Tumors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity. Radiology. 2007; 245(3):848-54. DOI: 10.1148/radiol.2452061535. View

15.

Brisse H, McCarville M, Granata C, Krug K, Wootton-Gorges S, Kanegawa K . Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011; 261(1):243-57. DOI: 10.1148/radiol.11101352. View

16.

Lewington V, Lambert B, Poetschger U, Sever Z, Giammarile F, McEwan A . I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel. Eur J Nucl Med Mol Imaging. 2016; 44(2):234-241. PMC: 5214990. DOI: 10.1007/s00259-016-3516-0. View

17.

Ladenstein R, Lambert B, Potschger U, Castellani M, Lewington V, Bar-Sever Z . Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging. 2017; 45(2):292-305. PMC: 5747549. DOI: 10.1007/s00259-017-3829-7. View

18.

Snay E, Treves S, Fahey F . Improved quality of pediatric 123I-MIBG images with medium-energy collimators. J Nucl Med Technol. 2011; 39(2):100-4. DOI: 10.2967/jnmt.110.080309. View

19.

Privitera L, Hales P, Musleh L, Morris E, Sizer N, Barone G . Comparison Between Diffusion-Weighted MRI and I-mIBG Uptake in Primary High-Risk Neuroblastoma. J Magn Reson Imaging. 2020; 53(5):1486-1497. PMC: 8246892. DOI: 10.1002/jmri.27458. View

20.

Siegel M, Jaju A . MR imaging of neuroblastic masses. Magn Reson Imaging Clin N Am. 2008; 16(3):499-513, vi. DOI: 10.1016/j.mric.2008.04.007. View